Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic peripheral artery disease (PAD), according to results from the STRIDE trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback